Nov 6 (Reuters) - Novo Nordisk expects global
sales to decline by low-single-digit percentage in 2026 after
the drugmaker unveiled a deal on Thursday to slash prices of
popular GLP-1 weight-loss drugs for U.S. government-backed
insurance programs and cash payers.